- Investors will be watching Intercept Pharmaceuticals (ICPT) closely today after a wild ride during the last four trading sessions.
- The company is set to present at the JPMorgan Healthcare Conference at 10:30 ET. Here's TheStreet's Adam Feuerstein: "[It's] going to be an adventure."
- Meanwhile, BofA's Rachel McMinn (who caused a stir by putting an $872 price target on the shares last week) is out in defense of the stock, which has fallen over the past two days.
- Ultimately, McMinn thinks investors need to be patient, given OCA's potential.
- ICPT +7% premarket